TEAM Trial: Exemestane vs Tamoxifen

(00:03:24) Elsevier Global Medical News, 2008 Dec 11, K Wachter

Dr. Stephen Jones is Medical Director, US Oncology Inc.

Dr. Jones discusses findings of the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial suggesting that the aromatase inhibitor exemestane improves disease-free and relapse-free survival over tamoxifen at 2.75 years of follow-up. In this, the first planned analysis of the phase III TEAM trial, women with ER+ early breast cancer who received exemestane also had longer time to distant metastasis than did those who received tamoxifen. 

See related videos to:
SABCS 2008

Related Links:

News Article: Exemestane Improves Survival Over Tamoxifen at 2.75 Years »
Commentary: The 2008 San Antonio Breast Cancer Symposium: Shaping the Standard of Care for 2009 »
Video: TEAM Trial Results—Critical Analysis »

Copyright © 2010 International Medical News Group
Subscribe Now »